Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.05. | Genelux GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
06.05. | Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates | 86 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter... ► Artikel lesen | |
06.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.04. | Benchmark maintains $25 target on Genelux stock, optimistic on trials | 1 | Investing.com | ||
GENELUX Aktie jetzt für 0€ handeln | |||||
31.03. | H.C. Wainwright maintains Buy on Genelux shares, target at $30 | 2 | Investing.com | ||
28.03. | Genelux GAAP EPS of -$0.95 misses by $0.07 | 1 | Seeking Alpha | ||
28.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
28.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 146 | GlobeNewswire (Europe) | - Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer - - Positive Preliminary Phase 1b/2... ► Artikel lesen | |
28.03. | GENELUX Corp - 10-K, Annual Report | 1 | SEC Filings | ||
26.03. | Benchmark maintains $25 target on Genelux following trial data | 1 | Investing.com | ||
25.03. | Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell | 1 | RTTNews | ||
25.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Genelux prices 3M shares at $3.50 in underwritten public offering | 3 | Seeking Alpha | ||
25.03. | Genelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer | 482 | GlobeNewswire (Europe) | - Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced... ► Artikel lesen | |
25.03. | Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
02.03. | Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 | 2 | Insider Monkey | ||
03.02. | Genelux Appoints Matthew Pulisic As CFO, Stock Drops | - | RTTNews | ||
03.02. | Genelux names Matthew Pulisic as CFO | 2 | Seeking Alpha | ||
03.02. | Genelux ernennt neuen CFO | - | Investing.com Deutsch | ||
03.02. | Genelux Corporation Announces New Chief Financial Officer | 155 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |